Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

NCT05065021 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
High Grade Serous Cancer
High Grade Endometrioid Cancer

Interventions

DRUG: Niraparib
DRUG: Dostarlimab
DRUG: Bevacizumab
DRUG: Paclitaxel

Sponsor

University Health Network, Toronto

Collaborators

[object Object]